Shaheenah Dawood, Consultant Medical Oncologist at Mediclinic Middle East, shared a post on LinkedIn:
“Wow!
Big news out today – adjuvant abemaciclib improves overall survival in high-risk ER+ breast cancer at ~7 years of follow-up!
I am looking forward to the data at ESMO25.”
More posts featuring Shaheenah Dawood on OncoDaily